

Vaccine Technologies Market Size Predicted to Hit USD 90.6 billion by 2033 at 6.4% CAGR, Says AMR

market is driven by rise in prevalence of infectious diseases, growing trend towards preventive healthcare, & government immunization programs and initiatives.

PORTLAND, OR, UNITED STATES, February 24, 2025 /EINPresswire.com/ -- Allied Market Research published a report, titled, "[Vaccine Technologies Market](#)" by Technology (Live Attenuated Vaccines, Inactivated Vaccines, Recombinant, Conjugate and Subunit Vaccines, Toxoid Vaccines, and Others), Delivery Method (Parenteral, Oral, and Nasal), and Type (Monovalent Vaccines, and Multivalent Vaccines): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the "vaccine technologies market" was valued at \$48.5 billion in 2023, and is estimated to reach \$90.6 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.



The growth of the vaccine technologies market is driven by rise in demand for vaccines due to rise in infectious diseases, advancements in biotechnology, and the growing focus on personalized medicine. Government initiatives to promote vaccination programs, along with rise in healthcare awareness, contribute to market expansion. In addition, rise in prevalence of chronic diseases and the need for effective immunization strategies worldwide continue to fuel the market growth. However, the cold chain storage and logistics challenges may restrain the market growth. On the other hand, technological advancement in vaccines provides an opportunity for the market growth.

For more information, please contact Allied Market Research at <https://www.alliedmarketresearch.com/request-sample/A172299>

For more information, please contact Allied Market Research at <https://www.alliedmarketresearch.com/request-sample/A172299>

- Sanofi

- Pfizer Inc.
- Emergent BioSolutions Inc
- AstraZeneca
- CSL Limited
- Sinovac Biotech Ltd.
- Bavarian Nordic
- Chongqing Zhifei Biological Products Co., Ltd.
- Merck & Co. Inc.
- GSK plc.
- Bharat Biotech International Limited

The report provides a detailed analysis of these key players in the vaccine technologies market. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to highlight the competitive scenario.

□□□□□□ □□□□□□□□□□ □□□□□ □□□□□□□□□□□□: -

By technology, the recombinant, conjugate and subunit vaccines segment held the largest market share in 2023, accounting for more than half of the vaccine technologies market revenue and is estimated to maintain its leadership status during the forecast period. This is attributed to their significant advantages in safety, efficacy, and adaptability. Recombinant vaccines are designed using genetic engineering techniques, allowing for the precise targeting of antigens, which results in enhanced immune responses and reduced side effects. This precision makes recombinant vaccines highly effective against a wide range of infectious diseases. Conjugate vaccines, which link polysaccharides to proteins, have been particularly successful in preventing bacterial diseases, such as meningitis and pneumonia, by boosting the immune response in young children and vulnerable populations. Subunit vaccines, containing only the essential pieces of pathogens (like proteins), offer improved safety profiles by reducing the risk of adverse reactions compared to traditional whole-pathogen vaccines.

By delivery method, the parenteral segment held the largest market share in 2023, accounting for more than four-fifth of the vaccine technologies market revenue. Parenteral administration, which includes routes like intramuscular, subcutaneous, and intradermal injections, ensures that vaccines are delivered directly into the bloodstream, providing a faster immune response compared to other delivery methods. This delivery method also allows for the precise control of dosage and the ability to target specific areas of the body for optimal immune stimulation. In addition, parenteral vaccines tend to have higher stability and efficacy, contributing to their widespread adoption in both routine and emergency vaccination programs.

By type, the multivalent vaccine segment held the largest market share in 2023, accounting for nearly two-third of the vaccine technologies market revenue and is estimated to maintain its leadership status during the forecast period. This is attributed to its ability to provide protection against multiple diseases with a single dose. This capability reduces the need for multiple

vaccinations, making it more convenient and cost-effective for both healthcare providers and patients. Multivalent vaccines are particularly important in regions with limited healthcare access, as they simplify immunization schedules and increase vaccination coverage. Furthermore, rise in prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased the demand for multivalent vaccines. Advances in biotechnology and development of more efficient production methods have also contributed to the growth of the segment, enabling manufacturers to produce these vaccines on a larger scale.

Region-wise, North America held the largest market share in 2023, accounting for almost half of the vaccine technologies market revenue, owing to its advanced healthcare infrastructure, significant investments in research and development, and strong presence of key pharmaceutical companies. The region benefits from well-established regulatory frameworks and a high level of innovation in vaccine technology, driving the adoption of new and improved vaccine solutions. In addition, North America's large population base and high level of awareness about immunization contribute to rise in demand for vaccines, further boosting the market growth.

However, Asia-Pacific is expected to register the highest CAGR during the forecast period, owing to rapid economic development, improving healthcare infrastructure, and increase in government initiatives focused on vaccination programs. Countries like India and China are investing heavily in the development of local vaccine production, which is expected to make vaccines more accessible and affordable to their large populations. Furthermore, rise in incidence of infectious diseases, along with rise in healthcare awareness is expected to drive the market growth.

For more information, visit: <https://www.alliedmarketresearch.com/purchase-enquiry/A172299>

Our research reports provide you with the following information:

- Which are the driving factors responsible for the growth of market?
- Which are the roadblock factors of this market?
- What are the new opportunities, by which market will grow in coming years?
- What are the trends of this market?
- Which are main factors responsible for new product launch?
- How big is the global & regional market in terms of revenue, sales and production?
- How far will the market grow in forecast period in terms of revenue, sales and production?
- Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
- Which region has more opportunities?

By Region Outlook

- North America
(U.S., Canada, Mexico)
- Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
- Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
- LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

□□□□□□ □□□□□□:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

□□□□ □□

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Market Research
+ 1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/788638079>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.